New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
04:55 EDTACRX, ACRX, BLRX, BLRX, CRIS, CRIS, NEO, NEO, PRTA, PRTA, PTCT, PTCT, LGND, LGND, GALE, GALE, IPCI, IPCIRoth Capital to hold a conference
ROTH Healthcare Corporate Access Day to be held in London, England on June 23-24.
News For ACRX;BLRX;CRIS;NEO;PRTA;PTCT;LGND;GALE;IPCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
16:05 EDTACRXAcelRx reports Q2 EPS (20c), consensus (26c)
Reports Q2 revenue $1.92M.
July 31, 2015
08:52 EDTLGNDAmgen results highlight Ligand royalty strength, says Roth Capital
Roth Capital notes Amgen (AMGN) reported Q2 Kyprolis sales of $119M compared to its estimate of $117M. The drug, alongside Promacta, represent the majority of Ligand's current royalty stream, the firm tells investors. It believes the growth of Kyprolis highlights Ligand's "strong core royalty bearing asset lineup." Roth keeps a Buy rating on the stock with a $135 price target.
July 30, 2015
16:39 EDTPTCTPTC Therapeutics reports Q2 EPS ($1.14), consensus ($1.20)
Reports Q2 revenue $6.8M, consensus $7.74M.
09:01 EDTLGNDLigand enters license, supply agreement with Sanofi
Subscribe for More Information
July 29, 2015
07:15 EDTGALEGalena announces U.S. product launch of Zuplenz Oral Soluble Film
Subscribe for More Information
06:38 EDTPTCTBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 28, 2015
12:16 EDTPRTAProthena moves higher following a positive mention by Navellier
Subscribe for More Information
July 27, 2015
06:13 EDTBLRXBioLineRx announces Bellerophon reported results from BCM clinical trial
Subscribe for More Information
July 24, 2015
12:44 EDTLGNDAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTLGNDFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
09:02 EDTLGNDLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
08:34 EDTACRXAcelRx's Zalviso recommended for marketing authorization by Europe's CHMP
AcelRx Pharmaceuticals announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, has adopted a positive opinion for Zalviso. The opinion, while not binding, recommends marketing authorization for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. Zalviso is an investigational drug-device combination product designed to deliver a sublingual formulation of sufentanil 15 mcg via a proprietary pre-programmed, non-invasive, patient-controlled device. The positive opinion by the CHMP will next be reviewed by the European Commission for central marketing authorization in the European Union. If approved, Grunenthal expects to launch Zalviso beginning in 1H16. In addition, AcelRx would be eligible to receive a $15M milestone payment from AcelRx's licensee in Europe, Grunenthal, upon approval. AcelRx had previously received CE Mark approval of the Zalviso device and ISO certification of its quality management system issued by the British Standards Institution.
July 23, 2015
07:51 EDTNEONeoGenomics lowers FY15 revenue guidance to 100M-$103M from $103M-$108M
Consensus $103.78M. NeoGenomics reiterated its expectation of a return to profitability in the second half of 2015.
07:21 EDTNEONeoGenomics reports Q2 EPS 0c, consensus (1c)
Subscribe for More Information
July 22, 2015
07:39 EDTPRTAProthena price target raised to $75 from $50 at RBC Capital
Subscribe for More Information
07:09 EDTNEONeoGenomics expands multimodality cancer profile testing
NeoGenomics expanded its comprehensive multimodality NeoTYPE tumor-type specific cancer profiling tests to include new profiles for head and neck tumors, pancreatic cancer, liver cancer, sarcoma, and for cancers of unknown primary. These new tests integrate a variety of technologies, including next generation sequencing, viral in-situ hybridization, FISH, and immunohistochemistry. A number of new tests are being added to NeoGenomics cancer diagnostic test menu.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use